Padma Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Padma Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress …

1981-01-21 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
PP Padma Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Padma Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Padma Pharmaceuticals is assessed as Low Risk with a Trust Score of 92/100. Padma Pharmaceuticals is an active private limited indian non-government company incorporated in 1981, operating in the Financial Services sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 18 Jul 2026 from the latest processed filings. Padma Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (17.75 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Bajaj Finance Limited1 48.0 cr
Others1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAJIV SHRIGOPAL BAJAJ 01234567 Director 01/04/2018 6 yrs Approved
SHRIGOPAL RANGNATH BAJAJ 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Vital Lifesciences Private Limited
Subsidiaries
-
Group entities
1
Capital events
4 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Pppl Maritius Private Limited Subsidiary Company 74.00%
Red Paw Pty. Ltd Subsidiary Company 74.00%
Vital Lifesciences Private Limited Holding Company 74.00%
Pidi Standard Biotech Limited Associate Company 74.00%
Vital Laboratories Private Limited Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
Operating for 45+ years.
Active GST registration(s).
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 17.75 cr already registered.
  • Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 13 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
31 Mar 2022
Share transfer (FY 2022)
39500.00000000 shares to SHRIGOPAL RANGNATH BAJAJ
28 Feb 2019
Charge created
Others - 6.75 cr
28 May 2015
Charge created
Bajaj Finance Limited - 11.00 cr
31 Mar 2014
Securities allotted
448400.00 Equity Shares - 2.51 cr raised
31 Mar 2013
Securities allotted
4970000.00 Equity Shares - 29.82 cr raised
10 Oct 2009
Securities allotted
2340000.00 Equity Shares - 11.70 cr raised
27 Mar 2009
Securities allotted
40000.00 Equity Shares - 20.00 Lakh raised
05 Dec 2008
Director ceased
RAVISH GOVIND MURARKA
22 Dec 1983
Director appointed
RAJIV SHRIGOPAL BAJAJ (Director)
21 Jan 1981
Incorporated
Registered with Roc Mumbai
Director appointed
SHRIGOPAL RANGNATH BAJAJ (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
4 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
S.B.Biotech Herbals Private Limited U24234GJ2006PTC047748 Navasari, Gujarat, India
Sain Processing And Weaving Mills Private Limited U74899DL1980PTC010607 New Delhi, Delhi, India
Basic Healthcare Products Private Limited U24230PB2006PTC030205 Punjab, Punjab, India
Trinity Paint Pluss Private Limited U24220HR2012PTC046197 Ballabgarh, Haryana, India
Mensa Medicare India Private Limited U24232RJ2008PTC027224 Jaipur, Rajasthan, India
Omarham Enterprises Private Limited U17299WB2019PTC233553 Kolkata, West Bengal, India
Viruj Chematrix Private Limited U24110TG2021PTC156000 Hyderabad, Telangana, India
Alkali Manufacturers Association Of India(Transfer Company From Maharashtra To U74899DL1994GAT056812 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Padma Pharmaceuticals before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Padma Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Padma Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Padma Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Padma Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Padma Pharmaceuticals an active company?

Padma Pharmaceuticals has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Padma Pharmaceuticals financially healthy?

Padma Pharmaceuticals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Padma Pharmaceuticals?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Padma Pharmaceuticals?

The ultimate holding entity is Vital Lifesciences Private Limited. 2 active director(s) are on record.

Does Padma Pharmaceuticals have loans or charges against its assets?

2 open charge(s) are registered against its assets.

Is Padma Pharmaceuticals up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Padma Pharmaceuticals?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.